Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 222   

Articles published

SNY 51.25 0.00 (0.00%)
price chart
Sanofi SA (ADR) Chief Strategy Officer Resigns; Company Facing Another ...
Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, is facing another turmoil as its chief strategy officer, David-Alexandre Gros, has resigned only six months after the company's famous chief executive officer, Chris Viehbacher, was ousted by ...
Driven By Amgen, Inc. And Sanofi SA (ADR), US Drug Price War May Shift From ...
As per research presented at the annual meeting of the American College of Cardiology in March and conducted separately by Amgen, Inc. (NASDAQ:AMGN), and Sanofi SA (ADR) (NYSE:SNY) along with its development partner Regeneron Pharmaceuticals ...
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS), Sanofi SA (ADR ...
The stocks include London-based GlaxoSmithKline plc (ADR) (NYSE:GSK), Switzerland-based Novartis AG (ADR) (NYSE:NVS) and France-based Sanofi SA (ADR) (NYSE:SNY). The veteran portfolio manager has an impressive track-record of managing to ...
Sanofi SA (ADR) (SNY) And Novartis AG Lead In US New Drug Approvals Since ...
According to a recent Bloomberg report, Sanofi SA (ADR) (NYSE:SNY) and Novartis AG (ADR) (NYSE:NVS) have launched the highest number of drugs in the US since 2009.
Sanofi SA (ADR) (SNY) Diabetes Drug Sales Disappoint; Trend Expected To ...
Sanofi SA (ADR) (NYSE:SNY) announced that the company's diabetes products saw a larger-than-expected drop in sales due to lower pricing of the company's star drug, Lantus.
Sanofi SA (ADR) (SNY) Upgraded To Outperform By Leerink Partners
Sanofi SA (ADR) (NYSE:SNY) stock was upgraded from a Market Perform rating to an Outperform rating by analysts at Leerink Swann & Company in a research report issued to clients on Tuesday.
A New Trend In The Treatment Of Cardiovascular Diseases; PCSK9 inhibitors  Stocks.org
Sanofi SA (ADR) Decides Against Discounting Toujeo More Than Lantus
Sanofi SA (ADR) (NYSE:SNY) has declared it will not offer steeper rebates for its newly approved insulin product Toujeo than those already existing on its older blockbuster version Lantus, soon to go off-patent in the US and EU.
GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR ...
Home > GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR): Are Big Pharma Stocks In Trouble?
Sanofi SA (ADR) May Launch Toujeo In The US On Monday
Sanofi SA ADR (NYSE:SNY) plans to launch its new insulin, Toujeo, for the treatment of diabetic patients in the US as early as this Monday, people familiar with the matter said.
Sanofi SA (ADR), Evotec Enter Into €250 million Strategic Alliance
Sanofi SA ADR (NYSE:SNY) on Saturday announced to transfer its research facility in Toulouse, France to Evotec AG ADR (OTCMKTS:EVTCY) in a deal worth €250 million.